Leigh Baxt, PhD, is a translational scientist and Drug Development Lead in the Therapeutics Bridge Labs (TxBL), where she advances early-stage therapeutics from discovery through in vivo validation to enable partnership and commercialization.
Leigh previously served as Director of Biology at the Tri-Institutional Therapeutics Discovery Institute and has contributed to more than 30 discovery programs across oncology, metabolic, infectious, and regenerative disease areas, with expertise across modalities including small molecules, PROTACs, ADCs, and emerging biologics platforms.
Leigh earned her PhD from Stanford University School of Medicine, completed postdoctoral training at Harvard Medical School, and holds a bachelor’s degree from Brown University.